Search results
Showing 541 to 555 of 1257 results for pathway
NICE has developed a medtech innovation briefing (MIB) on EpiFix for chronic wounds .
NICE has developed a medtech innovation briefing (MIB) on SYNE-COV for predicting COVID-19 outcomes .
NICE has developed a medtech innovation briefing (MIB) on the Neo Pedicle Screw System for spinal fusion surgery .
Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry (MIB113)
NICE has developed a medtech innovation briefing (MIB) on the Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry .
Cytosponge for detecting abnormal cells in the oesophagus (MIB240)
NICE has developed a medtech innovation briefing (MIB) on Cytosponge for detecting abnormal cells in the oesophagus .
Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias (MIB276)
NICE has developed a medtech innovation briefing (MIB) on Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias .
RespiraSense for continuously monitoring respiratory rate (MIB299)
NICE has developed a medtech innovation briefing (MIB) on RespiraSense for continuously monitoring respiratory rate .
NICE has developed a medtech innovation briefing (MIB) on TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation .
evidence review. Because of the limited evidence on the most effective pathway for excluding clinically significant progression of...
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.
NICE has developed a medtech innovation briefing (MIB) on MolecuLight i:X for wound imaging .
This quality standard covers testing, diagnosing and managing hepatitis B in adults, young people and children (from birth). It describes high-quality care in priority areas for improvement.
View quality statements for QS65Show all sections
Sections for QS65
- Quality statements
- Quality statement 1: Testing and vaccination for hepatitis B
- Quality statement 2: Referral for specialist care
- Quality statement 3: Referral to and assessment by specialist care for pregnant women who are identified as hepatitis B surface antigen-positive at antenatal screening
- Quality statement 4: Complete course of neonatal hepatitis B vaccination and blood testing at 12 months
- Quality statement 5: Personalised care plan
- Quality statement 6: Monitoring people with chronic hepatitis B infection who do not meet the criteria for antiviral treatment
- Quality statement 7: 6-monthly surveillance testing for hepatocellular carcinoma in adults with chronic hepatitis B infection who have significant liver fibrosis or cirrhosis
Ambu aScope4 Broncho for use in unexpected difficult airways (HTG312)
Evidence-based recommendations on Ambu aScope4 Broncho for use in unexpected difficult airways.
Artificial intelligence for analysing chest CT images (MIB243)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing chest CT images .
Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)
Evidence-based recommendations on upadacitinib (Rinvoq) for previously treated moderately to severely active Crohn’s disease in adults.